| abstract |
The present invention relates to heterotandem bicyclic peptide complexes that comprise a first peptide ligand, which binds to a component present in an immune cell, conjugated through a ligand to a second peptide ligand, which binds to a component present in a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in the prevention, suppression or treatment of cancer. |